Maple-Brown Louise J, Hughes Jaquelyne T, Lu Zhong X, Jeyaraman Kanakamani, Lawton Paul, Jones Graham Rd, Ellis Andrew, Sinha Ashim, Cass Alan, MacIsaac Richard J, Jerums George, O'Dea Kerin
Menzies School of Health Research, Charles Darwin University, Darwin, Australia ; Division of Medicine, Royal Darwin Hospital, Darwin, Australia.
Melbourne Pathology, Melbourne, Australia ; Department of Medicine, Monash University, Melbourne, Australia.
Diabetol Metab Syndr. 2014 Jul 16;6:78. doi: 10.1186/1758-5996-6-78. eCollection 2014.
Low levels of serum 25-hydroxy vitamin D (25(OH)D), have been associated with development of type 2 diabetes and cardiovascular disease (CVD); however there are limited data on serum 25(OH)D in Indigenous Australians, a population at high risk for both diabetes and CVD. We aimed to assess levels of serum 25(OH)D in Aboriginal and Torres Strait Islander Australians and to explore relationships between 25(OH)D and cardio-metabolic risk factors and diabetes.
592 Aboriginal and/or Torres Strait Islander Australian participants of The eGFR (estimated glomerular filtration rate) Study, a cross-sectional analysis of a cohort study performed in 2007-2011, from urban and remote centres within communities, primary care and tertiary hospitals across Northern Territory, Far North Queensland and Western Australia. Assessment of serum 25(OH)D, cardio-metabolic risk factors (central obesity, diabetes, hypertension, history of cardiovascular disease, current smoker, low HDL-cholesterol), and diabetes (by history or HbA1c ≥6.5%) was performed. Associations were explored between 25(OH)D and outcome measures of diabetes and number of cardio-metabolic risk factors.
The median (IQR) serum 25(OH)D was 60 (45-77) nmol/L, 31% had 25(OH)D <50 nmol/L. For participants with 25(OH)D < 50 vs ≥50 nmol/L, cardio-metabolic risk profile differed for: diabetes (54%, 36% p < 0.001), past history of cardiovascular disease (16%, 9%, p = 0.014), waist-hip ratio (0.98, 0.92, p < 0.001), urine albumin-creatinine ratio (2.7, 1.5 mg/mmol, p < 0.001). The OR (95% CI) for diabetes was 2.02 (1.03 - 3.95) for people in the lowest vs highest tertiles of 25(OH)D (<53 vs >72 nmol/L, respectively) after adjusting for known cardio-metabolic risk factors.
The percentage of 25(OH)D levels <50 nmol/L was high among Aboriginal and Torres Strait Islander Australians from Northern and Central Australia. Low 25(OH)D level was associated with adverse cardio-metabolic risk profile and was independently associated with diabetes. These findings require exploration in longitudinal studies.
血清25-羟基维生素D(25(OH)D)水平低与2型糖尿病和心血管疾病(CVD)的发生有关;然而,关于澳大利亚原住民血清25(OH)D的数据有限,这是一个糖尿病和CVD高危人群。我们旨在评估澳大利亚原住民和托雷斯海峡岛民的血清25(OH)D水平,并探讨25(OH)D与心脏代谢危险因素及糖尿病之间的关系。
对2007 - 2011年进行的一项队列研究的横断面分析——估算肾小球滤过率(eGFR)研究中的592名澳大利亚原住民和/或托雷斯海峡岛民参与者进行研究,这些参与者来自北领地、昆士兰远北地区和西澳大利亚州社区、初级保健机构及三级医院的城市和偏远中心。对血清25(OH)D、心脏代谢危险因素(中心性肥胖、糖尿病、高血压、心血管疾病史、当前吸烟者、低高密度脂蛋白胆固醇)和糖尿病(根据病史或糖化血红蛋白≥6.5%)进行评估。探讨25(OH)D与糖尿病结局指标及心脏代谢危险因素数量之间的关联。
血清25(OH)D的中位数(四分位间距)为60(45 - 77)nmol/L,31%的人25(OH)D <50 nmol/L。对于25(OH)D <50 vs≥50 nmol/L的参与者,在以下方面心脏代谢风险状况存在差异:糖尿病(54%,36%,p <0.001)、心血管疾病既往史(16%,9%,p = 0.014)、腰臀比(0.98,0.92,p <0.001)、尿白蛋白肌酐比值(2.7,1.5 mg/mmol,p <0.001)。在调整已知的心脏代谢危险因素后,25(OH)D处于最低三分位数与最高三分位数的人群(分别为<53 vs>72 nmol/L)患糖尿病的比值比(95%置信区间)为2.02(1.03 - 3.95)。
在澳大利亚北部和中部的原住民和托雷斯海峡岛民中,25(OH)D水平<50 nmol/L的比例较高。低25(OH)D水平与不良的心脏代谢风险状况相关,且与糖尿病独立相关。这些发现需要在纵向研究中进一步探索。